Skip Navigation

Gilead CEO: Oral version of Covid drug Remdesivir in early testing

In this video

GILD

Squawk on the Street

Gilead CEO: Oral version of Covid drug Remdesivir in early testing

Gilead CEO Daniel O’Day sits down with CNBC's Meg Tirrell and the 'Squawk on the Street' team to discuss the company's Covid-19 antiviral, Remdesivir.

04:32

Mon, Jan 10 202211:19 AM EST

Dow closes above 40,000 points for first time in history

Dow closes above 40,000 points for first time in history

Financials and utilities will benefit from a Fed rate cut, says Ned Davis' Ed Clissold

Financials and utilities will benefit from a Fed rate cut, says Ned Davis' Ed Clissold

Generative-AI startups like OpenAI beginning to monetize their cutting-edge technology

Generative-AI startups like OpenAI beginning to monetize their cutting-edge technology

How fintech start-up Hiive facilitates pre-IPO investing

How fintech start-up Hiive facilitates pre-IPO investing

How FICO leverages AI to optimize credit score decisions

How FICO leverages AI to optimize credit score decisions

Dow closes above 40,000 points for first time in history

Dow closes above 40,000 points for first time in history

Financials and utilities will benefit from a Fed rate cut, says Ned Davis' Ed Clissold

Financials and utilities will benefit from a Fed rate cut, says Ned Davis' Ed Clissold

Generative-AI startups like OpenAI beginning to monetize their cutting-edge technology

Generative-AI startups like OpenAI beginning to monetize their cutting-edge technology

How fintech start-up Hiive facilitates pre-IPO investing

How fintech start-up Hiive facilitates pre-IPO investing

How FICO leverages AI to optimize credit score decisions

How FICO leverages AI to optimize credit score decisions